Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term IKERVIS study in dry eye disease with severe keratitis
2017-002660-41Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclosporine in dry eye syndrome (DED) and keratitis, sponsored by Santen Pharmaceutical. Primary endpoint: Correlation between corneal fluorescein staining and symptoms. Started Feb 2019; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)keratitis
Beyond the preview
Go deeper on 2017-002660-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002660-41.